Skip to main content
Emergent BioSolutions Inc. logo

Emergent BioSolutions Inc. — Investor Relations & Filings

Ticker · EBS ISIN · US29089Q1058 LEI · 549300YW6TUOX8BE5103 US Manufacturing
Open in API
Filings indexed 1,264 across all filing types
Latest filing 2014-02-04 Capital/Financing Update
Country US United States of America
Listing US EBS

About Emergent BioSolutions Inc.

https://emergentbiosolutions.com/

Emergent BioSolutions Inc. is a life sciences company specializing in solutions for public health threats. The company develops, manufactures, and delivers medical countermeasures for national security and public health preparedness, addressing threats such as anthrax, smallpox, botulism, and Ebola. In addition to its biodefense portfolio, Emergent provides commercial products for endemic health crises, notably the opioid epidemic. The company also offers contract development and manufacturing services through strategic partnerships, leveraging its specialized capabilities to support biopharmaceutical innovators, governments, and non-governmental organizations.

Recent filings

Filing Released Lang Actions
Capital/Financing Update 2014
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce significant events. The content describes the completion of a $250 million convertible senior notes offering and related credit facility changes, including repayment and termination of certain loans. This is an update on the company's financing activities, specifically capital raising and debt management. The document is relatively short (2896 characters) and focuses on a financing event rather than a full financial report or earnings release. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2014-02-04 English
FORM 4
Director's Dealing
2014-02-03 English
Capital/Financing Update 2014
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated January 29, 2014, reporting the entry into a material definitive agreement related to the issuance and sale of convertible senior notes. It includes detailed descriptions of the purchase agreement, indenture, terms of the notes, and related financial obligations. The document also references press releases and exhibits related to the transaction. The content focuses on a financing transaction and capital structure update rather than a full financial report, earnings release, or management discussion. Therefore, this filing is best classified as a Capital/Financing Update (CAP). The document length and detail confirm it is not a brief announcement or a regulatory filing fallback.
2014-01-29 English
Major Shareholding Notification 2014
Major Shareholding Notification
2014-01-29 English
Major Shareholding Notification 2014
Major Shareholding Notification
2014-01-28 English
Regulatory Filings 2014
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated January 22, 2014. It announces the company's intention to offer convertible senior notes and provides details about an acquisition arrangement with Cangene Corporation. The filing includes audited and unaudited financial statements of Cangene as exhibits, as well as pro forma combined financial statements reflecting the acquisition and offering. The document is not itself an annual or interim report but a regulatory filing to disclose significant events and financial information related to the acquisition and financing. It contains substantive financial data but is primarily a current report on significant corporate events and related financial disclosures. Therefore, the appropriate classification is Regulatory Filings (RNS).
2014-01-22 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.